Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dovitinib monotherapy as salvage treatment in FGFR2-amplified metastatic or unresectable gastric cancer
KCT0001256Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in gastric cancer (GC), sponsored by Novartis. Started Jan 2013; status: recruiting.
02
Drugs
dovitinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0001256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001256.